# Clinical Study of Camrelizumab Combined With SOX in the Adjuvant Treatment of Advanced Gastric Adenocarcinoma or Gastric Esophageal Junction Adenocarcinoma

> **NCT05184946** · PHASE2 · UNKNOWN · sponsor: **The Second Affiliated Hospital of Shandong First Medical University** · enrollment: 72 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Camrelizumab Combined with SOX

## Key facts

- **NCT ID:** NCT05184946
- **Lead sponsor:** The Second Affiliated Hospital of Shandong First Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-10-09
- **Primary completion:** 2025-10-08
- **Final completion:** 2025-10-08
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2022-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05184946

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05184946, "Clinical Study of Camrelizumab Combined With SOX in the Adjuvant Treatment of Advanced Gastric Adenocarcinoma or Gastric Esophageal Junction Adenocarcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05184946. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*